help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

The Oncologist, Vol. 10, No. 8, 623-631, September 2005; doi:10.1634/theoncologist.10-8-623
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaeffer, D. T.
Right arrow Articles by Randall, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaeffer, D. T.
Right arrow Articles by Randall, M. E.

Adjuvant Radiotherapy in Endometrial Carcinoma

David T. Shaeffera, Marcus E. Randallb

a Therapeutic Radiologists, Inc., Kansas City, Missouri, USA; b Leo W. Jenkins Cancer Center, The Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA

Correspondence: David Shaeffer, M.D., Therapeutic Radiologists, Inc., 6600 Winchester, Suite 230, Kansas City, MO 64133, USA. Telephone: 816-313-6006; Fax: 816-313-6000; e-mail: dshaeffer{at}sbcglobal.net

Endometrial cancer is a common female malignancy, affecting approximately 40,000 women per year. Despite the publication of several prospective randomized trials, there continues to be controversy regarding the use of adjuvant radiation therapy in endometrial cancer management. It is clear that most women with early-stage, low-risk disease will do well without adjuvant therapy. Intermediate-risk patients are at risk for local-regional relapse, and radiotherapy has been shown to effectively reduce this risk without significantly impacting overall survival. The absence of a clear impact on survival has resulted in a lack of consensus regarding the use of radiotherapy in intermediate-risk patients. At the same time, the patterns of failure in intermediate-risk patients have resulted in differing recommendations regarding appropriate radiotherapy targets. High-risk patients are at risk for both local and distant failure, and chemotherapy has been shown to improve outcome in these patients. High-risk patients are also at risk for local failure, and targeted radiotherapy may be appropriate. In this article, we discuss the controversies surrounding the use of adjuvant radiotherapy in endometrial cancer using an evidence-based approach.

Key Words. Radiation • Endometrial cancer • Hysterectomy • Local-regional recurrence






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.